This enables exploration of mechanisms underlying GLP-1, PYY and glucagon release, with the potential to identify targets in proglucagon-expressing cells that could be exploited therapeutically for the treatment of diabetes and obesity.
To find out more about how this website collects your personal data see www.enterprise.cam.ac.uk/about-us/information-compliance/data-protection/core-privacy-notices/website-users-use-personal-information/